Quantitative scale validation of the Dimensional Anhedonia Rating Scale in the treatment of Chinese patients with major depressive disorder
This study comprehensively evaluated the measurement properties of the DARS using a Chinese population with MDD. Overall, the Chinese version of DARS demonstrates good psychometric properties and has been found to be responsive to change during antidepressant treatment. The DARS is a suitable scale for assessing patient-reported anhedonia in future clinical trials.
Authors
- Carol Jamieson (ORCID: https://orcid.org/0000-0001-9160-0746)
- Heather Rozjabek
- Tianmei Si (ORCID: https://orcid.org/0000-0001-9823-2720)
- Yun‐Ai Su (ORCID: https://orcid.org/0000-0001-8445-9633)
- Jingyu Lin (ORCID: https://orcid.org/0000-0001-6215-3211)
- Dong‐Jing Fu (ORCID: https://orcid.org/0000-0001-6829-0743)
- Xiaojing Gu (ORCID: https://orcid.org/0000-0002-9023-725X)
- Donald M. Bushnell (ORCID: https://orcid.org/0000-0001-9226-1678)
- Xiaowei Chen (ORCID: https://orcid.org/0000-0001-6466-6248)
Institutions
- Johnson & Johnson (United States) (US)
- Peking University (CN)
- Institute for Patient- and Family-Centered Care (US)
- Johnson & Johnson (United Kingdom) (GB)
- Peking University Sixth Hospital (CN)
Publication Details
- Journal
- General Psychiatry
- Published
- 2025-04-01
- DOI
- https://doi.org/10.1136/gpsych-2024-101789
- Citations
- 1
- Primary Topic
- Treatment of Major Depression
- Type
- article
- Field-Weighted Citation Impact
- 1.39
Funders
- National Natural Science Foundation of China